NL
BMY icon

NWAM LLC’s Bristol-Myers Squibb BMY Stock Holding History

NWAM LLC’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
22,690
+8,102
+56% +$472K 0.08% 235
2025
Q4 		$795K Buy
14,588
+2,595
+22% +$125K 0.04% 316
2025
Q3 		$526K Sell
11,993
-627
-5% -$29.3K 0.03% 400
2025
Q2 		$553K Sell
12,620
-7,838
-38% -$385K 0.03% 371
2025
Q1 		$1.25M Buy
20,458
+1,985
+11% +$116K 0.11% 176
2024
Q4 		$1.04M Buy
18,473
+551
+3% +$30.8K 0.06% 255
2024
Q3 		$927K Buy
+17,922
New +$841K 0.06% 284
2024
Q2 		– Sell
-18,700
Closed -$845K – 196
2024
Q1 		$845K Sell
18,700
-196
-1% -$9.98K 0.07% 250
2023
Q4 		$970K Buy
18,896
+921
+5% +$48.3K 0.08% 235
2023
Q3 		$1.04M Sell
17,975
-8,249
-31% -$505K 0.11% 186
2023
Q2 		$1.68M Sell
26,224
-31,718
-55% -$2.13M 0.14% 146
2023
Q1 		$4.02M Sell
57,942
-3,136
-5% -$221K 0.41% 59
2022
Q4 		$4.39M Buy
61,078
+42,402
+227% +$3.2M 0.39% 61
2022
Q3 		$1.33M Buy
18,676
+1,634
+10% +$119K 0.13% 165
2022
Q2 		$1.3M Sell
17,042
-1,532
-8% -$117K 0.12% 165
2022
Q1 		$1.36M Buy
18,574
+182
+1% +$12.2K 0.1% 192
2021
Q4 		$1.15M Buy
18,392
+4,571
+33% +$268K 0.09% 216
2021
Q3 		$818K Buy
13,821
+2,085
+18% +$137K 0.07% 238
2021
Q2 		$784K Sell
11,736
-691
-6% -$45.1K 0.07% 241
2021
Q1 		$785K Sell
12,427
-774
-6% -$48.2K 0.08% 239
2020
Q4 		$819K Buy
13,201
+1,063
+9% +$65.4K 0.09% 200
2020
Q3 		$732K Sell
12,138
-1,167
-9% -$70.2K 0.12% 146
2020
Q2 		$782K Buy
13,305
+462
+4% +$27.6K 0.11% 177
2020
Q1 		$716 Buy
12,843
+48
+0.4% +$2.93K 0.02% 183
2019
Q4 		$821K Buy
12,795
+1,253
+11% +$71.8K 0.14% 154
2019
Q3 		$585K Sell
11,542
-573
-5% -$26.9K 0.11% 179
2019
Q2 		$549K Sell
12,115
-159
-1% -$7.41K 0.11% 184
2019
Q1 		$586K Buy
12,274
+100
+0.8% +$4.98K 0.13% 164
2018
Q4 		$633K Sell
12,174
-1,908
-14% -$103K 0.16% 141
2018
Q3 		$874K Buy
14,082
+301
+2% +$17.9K 0.2% 113
2018
Q2 		$763K Sell
13,781
-1,505
-10% -$81.3K 0.18% 131
2018
Q1 		$967K Sell
15,286
-333
-2% -$21.4K 0.24% 98
2017
Q4 		$957K Buy
15,619
+875
+6% +$54.7K 0.24% 102
2017
Q3 		$940K Sell
14,744
-306
-2% -$17.9K 0.24% 102
2017
Q2 		$839K Sell
15,050
-3,165
-17% -$172K 0.15% 110
2017
Q1 		$991K Buy
18,215
+2,405
+15% +$132K 0.3% 79
2016
Q4 		$924K Buy
15,810
+307
+2% +$16.8K 0.31% 82
2016
Q3 		$836K Sell
15,503
-226
-1% -$14.5K 0.06% 93
2016
Q2 		$1.16M Buy
15,729
+126
+0.8% +$8.9K 0.45% 56
2016
Q1 		$997K Sell
15,603
-267
-2% -$16.8K 0.4% 63
2015
Q4 		$1.09M Sell
15,870
-130
-0.8% -$8.59K 0.45% 57
2015
Q3 		$918K Hold
16,000
– – 0.76% 30
2015
Q2 		$1.09M Buy
16,000
+643
+4% +$42.4K 0.46% 56
2015
Q1 		$991K Buy
15,357
+225
+1% +$14.1K 0.42% 60
2014
Q4 		$893K Sell
15,132
-10,690
-41% -$603K 0.39% 65
2014
Q3 		$1.32M Sell
25,822
-24,814
-49% -$1.24M 0.47% 54
2014
Q2 		$2.46M Buy
50,636
+3,356
+7% +$165K 0.76% 35
2014
Q1 		$2.46M Buy
47,280
+16,279
+53% +$866K 0.84% 34
2013
Q4 		$1.65M Sell
31,001
-16,452
-35% -$838K 0.87% 39
2013
Q3 		$2.2M Sell
47,453
-1,689
-3% -$74.1K 1.07% 32
2013
Q2 		$2.2M Buy
+49,142
New +$2.13M 1.11% 29

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NWAM LLC's BMY Position: Q1 2026 in Review

NWAM LLC increased its Bristol-Myers Squibb (BMY) stake by 56% in Q1 2026, buying an estimated $472K and bringing the position to 22,690 shares worth $1.38M. The position accounts for 0.08% of the portfolio, ranked #235.

NWAM LLC first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $4.39M in Q4 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • NWAM LLC held 22,690 shares of Bristol-Myers Squibb worth $1.38M as of Q1 2026.
  • NWAM LLC bought 8,102 Bristol-Myers Squibb shares in Q1 2026, an estimated $472K.
  • Bristol-Myers Squibb made up 0.08% of NWAM LLC's portfolio in Q1 2026, its #235 holding.
  • NWAM LLC first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
  • NWAM LLC's Bristol-Myers Squibb position peaked at $4.39M in Q4 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on NWAM LLC's 13F filing for Q1 2026, filed 4 May 2026.